Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  McCarty, M. F.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Over-the-Counter Chromium and Renal Failure

right arrow Mark F. McCarty

15 October 1997 | Volume 127 Issue 8 (Part 1) | Pages 654-655


TO THE EDITOR:

Dr. Wasser and colleagues [1] suggest that a case of chronic active interstitial nephritis may have been attributable to previous ingestion of the nutritional supplement chromium picolinate. It appears that the authors are unaware of the major differences in the toxicology of hexavalent and trivalent forms of chromium. Hexavalent chromium is an unstable oxidizing compound that has induced acute tubular necrosis in episodes of industrial poisoning; long-term exposure in persons who work with chromium is associated with low-molecular-weight proteinuria [2]. In contrast, the nutritionally essential trivalent form of chromium is stable and essentially nontoxic on oral administration. A careful literature review failed to reveal any reports in which trivalent chromium, administered orally in any dose to animals or humans, induced renal toxicity or any lesion other than transient gastrointestinal irritation associated with massive bolus doses. Several reports indicate that high doses of parenteral trivalent chromium-for example, 2 mg/kg intraperitoneally daily for several weeks-can induce proximal tubular damage in rodents [3]; it is impossible to achieve oral absorption of such pathogenic doses because of the limited solubility and inefficient absorbability of trivalent complexes. In the judgment of the Environmental Protection Agency, daily ingestion of as much as 70 000 µg of trivalent chromium on a continuing basis would probably be safe [4]. Dr. Wasser's patient ingested 600 µg daily.

With regard to chromium picolinate specifically-a complex of trivalent chromium with the natural metabolite picolinic acid-a recent toxicology study found no histologic damage in rats who ingested up to 100 ppm chromium as chromium picolinate for 6 months [5]. Controlled clinical studies with chromium picolinate, done using daily doses of chromium as high as 1000 µg, found no perturbations of renal function or any other adverse effects, and no previous anecdotal reports have linked this nutrient to renal damage in more than 30 million person-years of use.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Nutrition 21; San Diego, CA 92109


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Wasser WG, Feldman NS, D'Agati VD. Chronic renal failure after ingestion of over-the-counter chromium picolinate [Letter]. Ann Intern Med. 1997; 126:410.

2. Wedeen RP, Qian L. Chromium-induced kidney disease. Environ Health Persp. 1991; 92:71-4.

3. Mather AK, Chandra SV, Tandon SK. Comparative toxicity of trivalent and hexavalent chromium to rabbits. II. Morphological changes in some organs. Toxicology. 1977; 8:53-61.

4. Mertz W. Risk assessment of essential trace elements: new approaches to setting recommended dietary allowances and safety limits. Nutr Rev. 1995; 53:179-85.

5. Anderson RA, Bryden NA, Polansky MM. Lack of toxicity of chromium chloride and chromium picolinate in rats. J Am Coll Nutr. 1997; 16:273-9.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  McCarty, M. F.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online